• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Obstetrics and Gynecology

UCLA Obstetrics and Gynecology

UCLA Obstetrics and Gynecology
  • About Us
    • Chair's Welcome
    • Contact Us
    • Giving
    • Job Listings
    • News
    • Webinars
  • Clinical Programs
    • Chronic Pelvic Pain Program
    • Family Planning
    • Fertility and Reproductive Health Center
    • Fibroid Treatment Program
    • Gynecologic Oncology
    • Gynecology
    • Labor and Delivery
    • Maternal Fetal Medicine
    • Nurse Midwives
    • Minimally Invasive & Robotic Surgery
    • Obstetrics
    • Women's Pelvic Health
  • Conditions Treated
    • Cervical Cancer
    • Cervical Insufficiency
    • Congenital Abnormalities
    • Endometriosis
    • Fibroids
    • Hirsutism
    • Infertility
    • Menopause
    • Ovarian Fallopian Tube and Primary Peritoneal Cancer
    • Polycystic Ovary Syndrome (PCOS)
    • Pregnancy
    • Premenstrual Syndrome (PMS)
    • Recurrent Pregnancy Loss
    • Reproductive Surgery
    • Sexually-transmitted Diseases
    • Urinary Incontinence
    • Urinary Tract Infection
    • Uterine / Endometrial Cancer
    • Vaginal Yeast Infection
    • Vulvar and Vaginal Cancer
    • Vulvodynia
  • For Patients
    • Coronavirus
    • Patient Stories
    • myUCLAhealth
    • Appointments
    • Clinical Updates
    • FAQs
    • Find a Doctor
    • First Visit
    • Health Plans
    • Locations
    • Medical Records
    • Patient Videos
    • Physicians Update
    • Pregnancy
    • Prescription Refill
    • Resources
    • Vital Signs Newsletters
    • Webinars
  • Clinical Trials
  • Research
    • Yalda Afshar MD PhD Lab
    • Sandra Orsulic PhD Lab
    • Women's Reproductive Health Research Program
  • Education
    • Residency
    • Fellowship Programs
    • Housestaff Roster 2020-21
    • Calendar of Events
    • Grand Rounds and Conferences
    • Medical Students
    • Aerial Tour: Why Choose UCLA?
    • Contact Academic Office
  • Our Expert Team
    • Appointment Request
    • Chronic Pelvic Pain
    • Family Planning
    • Fertility & Reproductive Health
    • Fibroid Treatment
    • Gynecologic Oncology
    • Gynecology
    • Minimally Invasive & Robotic Surgery
    • Nurse Midwives
    • Obstetrics
    • Maternal Fetal Medicine
    • Women's Pelvic Health
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Obstetrics and Gynecology

Clinical Trials

  1. Home
  2. Clinical Trials
  3. NCI COVID-19 in Cancer Patients

NCI COVID-19 in Cancer Patients

Share this

NCI COVID-19 in Cancer Patients, or NCCAPS Study 

This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.  The Principal Investigators of this study are Dr. Beth Y. Karlan and Dr. Gottfrield Konecny.

Participants must meet the following criteria:

  • Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy) that fits into any one of the following categories:
    • Patient is receiving active treatment (defined as current treatment or treatment within the past 6 weeks) for metastatic cancer. Eligible treatment types are chemotherapy, immunotherapy, monoclonal antibody therapy (e.g., rituximab, trastuzumab, cetuximab), targeted therapy (e.g., BRAF/MEK inhibitor, EGF-R inhibitor), endocrine therapy, or radiation therapy; or
    • Patients is receiving adjuvant treatment for non-metastatic (stage I-III) cancer and has received intravenous chemotherapy, immunotherapy, targeted therapy, or radiation therapy within the past 6 weeks; or
    • Patient has received an allogenic stem cell transplant or chimeric antigen receptor (CAR)-T cell or other modified cellular therapy at any time; or
    • Patient is currently receiving treatment or prophylaxis for graft versus (vs.) host disease; or
    • Patient has received an autologous bone marrow transplant within the past 2 years.
  • Patient must have a documented positive SARS CoV-2 test. The positive test results must have been received no earlier than 14 days prior to enrollment.  The test must have been ordered by a doctor's office, hospital, or department of public health. Any specimen source (e.g., nasopharyngeal swab, oropharyngeal swab, etc.) is allowable for the SARS CoV-2 test.

Of note, patients who have recently received a SARS CoV-2 test may also be eligible to sign consent but will only be enrolled if final test result is positive.

If you would like more information please contact the Women’s Health Clinical Research Unit.
Email: obgynresearch@mednet.ucla.edu or Call: 310-794-9652.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest